Home » Stocks » AC Immune

AC Immune SA (ACIU)

Stock Price: $6.70 USD 0.10 (1.52%)
Updated Aug 7, 2020 12:03 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 481.46M
Revenue (ttm) 114.46M
Net Income (ttm) 46.85M
Shares Out 71.86M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $6.70
Previous Close $6.60
Change ($) 0.10
Change (%) 1.52%
Day's Open 6.60
Day's Range 6.55 - 6.84
Day's Volume 240,843
52-Week Range 4.07 - 13.00

More Stats

Market Cap 481.46M
Enterprise Value 186.48M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 71.86M
Float 26.86M
EPS (basic) n/a
EPS (diluted) -0.55
FCF / Share 0.81
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 11.42%
Payout Ratio n/a
Shares Short 627,105
Short Ratio 9.40
Short % of Float 2.29%
Beta 0.50
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 8.76
PS Ratio 4.21
PB Ratio 1.74
Revenue 114.46M
Operating Income 45.91M
Net Income 46.85M
Free Cash Flow 54.99M
Net Cash 294.97M
Net Cash / Share 4.10
Gross Margin 100.00%
Operating Margin 40.11%
Profit Margin 40.90%
FCF Margin 48.04%
ROA -4.77%
ROE -10.18%
ROIC 80.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$12.70*
(89.60% upside)
Low
8.61
Current: $6.70
High
17.89
Target: 12.70
*Average 12-month USD price target from 4 stock analysts.

Financial Performance

Financial numbers in millions CHF.

Financial Overview

Year201920182017201620152014
Revenue1117.1920.2623.2139.0930.27
Revenue Growth1443.31%-64.48%-12.75%-40.61%29.14%-
Gross Profit1117.1920.2623.2139.0930.27
Operating Income44.54-49.55-22.54-10.4618.6210.72
Net Income45.44-50.95-26.41-7.1020.2710.74
Shares Outstanding67.5657.3657.0850.1043.4142.68
Earnings Per Share0.64-0.82-0.46-0.140.440.24
EPS Growth----83.33%-
Operating Cash Flow55.23-43.77-22.27-5.5644.04-17.64
Capital Expenditures-1.89-1.86-1.80-0.90-0.24-0.13
Free Cash Flow53.34-45.63-24.07-6.4643.79-17.77
Cash & Equivalents28918612415276.523.31
Total Debt2.470.520.49---
Net Cash / Debt28618612415276.523.31
Assets29919713215679.9330.30
Liabilities26.8118.9315.1713.728.896.83
Book Value27217811714271.0423.47
Numbers in millions CHF, except per-share numbers.

Company Profile

Company Details

Full Name AC Immune SA
Country Switzerland
Employees 115
CEO Andrea Pfeifer

Stock Information

Ticker Symbol ACIU
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ACIU
IPO Date September 23, 2016

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.